Abstract:Lung cancer is the leading cause of cancer death due, in part, to lack of early diagnostic tools. Bronchoscopy represents a relatively noninvasive initial diagnostic test in smokers with suspect disease, but it has low sensitivity. We have reported a gene expression profile in cytologically normal large airway epithelium obtained via bronchoscopic brushings, which is a sensitive and specific biomarker for lung cancer. Here, we evaluate the independence of the biomarker from other clinical risk factors and determine the performance of a clinicogenomic model that combines clinical factors and gene expression. Training (n = 76) and test (n = 62) sets consisted of smokers undergoing bronchoscopy for suspicion of lung cancer at five medical centers. Logistic regression models describing the likelihood of having lung cancer using the biomarker, clinical factors, and these data combined were tested using the independent set of patients with nondiagnostic bronchoscopies. The model predictions were also compared with physicians' clinical assessment. The gene expression biomarker is associated with cancer status in the combined clinicogenomic model (P < 0.005). There is a significant difference in performance of the clinicogenomic relative to the clinical model (P < 0.05). In the test set, the clinicogenomic model increases sensitivity and negative predictive value to 100% and results in higher specificity (91%) and positive predictive value (81%) compared with other models. The clinicogenomic model has high accuracy where physician assessment is most uncertain. The airway gene expression biomarker provides information about the likelihood of lung cancer not captured by clinical factors, and the clinicogenomic model has the highest prediction accuracy. These findings suggest that use of the clinicogenomic model may expedite more invasive testing and definitive therapy for smokers with lung cancer and reduce invasive diagnostic procedures for individuals without lung cancer.

Probabilistic Lung Cancer Models Conditioned on Gene Expression Microarray Data

LUADpp: an Effective Prediction Model on Prognosis of Lung Adenocarcinomas Based on Somatic Mutational Features

Identification of Genes Associated with Lung Adenocarcinoma Prognosis

A Robust Hybrid Approach Based on Estimation of Distribution Algorithm and Support Vector Machine for Hunting Candidate Disease Genes.

Survival ensembles by the sum of pairwise differences with application to lung cancer microarray studies

Gene Selection for Cancer Clustering Analysis Based on Expression Data

Independent Component Analysis-Based Penalized Discriminant Method for Tumor Classification Using Gene Expression Data.

Cancer prediction with gene expression profiling and differential evolution

Bayesian variable selection for disease classification using gene expression data

Analysis of Gene Expression Profiles of Lung Cancer Subtypes with Machine Learning Algorithms.

A large cohort study identifying a novel prognosis prediction model for lung adenocarcinoma through machine learning strategies

Integrating genetic mutations and expression profiles for survival prediction of lung adenocarcinoma

Integrating Biological Knowledge with Gene Expression Profiles for Survival Prediction of Cancer

On Gene Selection and Classification for Cancer Microarray Data Using Multi-Step Clustering and Sparse Representation

Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma

Ensemble gene selection for cancer classification

Integrative analysis of multiple cancer prognosis studies with gene expression measurements.

An integrative analysis of cancer gene expression studies using Bayesian latent factor modeling

Histopathological imaging features- versus molecular measurements-based cancer prognosis modeling

A Prediction Model for Lung Cancer Diagnosis that Integrates Genomic and Clinical Features

Machine-learning and scRNA-Seq-based diagnostic and prognostic models illustrating survival and therapy response of lung adenocarcinoma